We are live on
!
Find out more
TSC
Two Seas Capital Portfolio holdings
AUM
$7.15B
1-Year Est. Return
169.27%
This Fund
S&P 500
This Quarter
Est. Return
+9.47%
1 Year Est. Return
+169.27%
3 Year Est. Return
+279.82%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$348M
(+320%)
Cap. Flow
+$320M
Cap. Flow
% of AUM
70%
Top 10 Holdings %
Top 10 Hldgs %
99.09%
Holding
14
New
3
Increased
5
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Indivior Pharmaceuticals
INDV
|
+$313M |
| 2 |
Meta Platforms (Facebook)
META
|
+$4.94M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$4.11M |
| 4 |
Arcutis Biotherapeutics
ARQT
|
+$2.58M |
| 5 |
Arbutus Biopharma
ABUS
|
+$2.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hertz
HTZ
|
+$5.06M |
| 2 |
Burford Capital
BUR
|
+$3.03M |
| 3 |
Sonos
SONO
|
+$2.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.23% |
| 2 | Communication Services | 1.88% |
| 3 | Materials | 1.08% |
| 4 | Industrials | 0.74% |
| 5 | Technology | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Indivior Pharmaceuticals
INDV
$4.58B
| $325M | 71.11% |
+13,668,919
| New | +$313M |
|
2
Roivant Sciences
ROIV
$25B
| $79.7M | 17.43% |
7,909,591
+102,484
| +1% | +$917K |
|
|
3
Arbutus Biopharma
ABUS
$913M
| $19M | 4.16% |
8,280,818
+816,094
| +11% | +$2.12M |
|
|
4
Meta Platforms (Facebook)
META
$1.5T
| $8.61M | 1.88% |
30,003
+20,000
| +200% | +$4.94M |
|
5
Odyssey Marine Exploration
OMEX
$43.5M
| $4.94M | 1.08% |
1,371,874
| – | – |
|
|
ESPR
6
DELISTED
Esperion Therapeutics
ESPR
| $4.09M | 0.89% |
+2,941,872
| New | +$4.11M |
|
|
7
Hertz
HTZ
$493M
| $3.38M | 0.74% |
183,909
-308,473
| -63% | -$5.06M |
|
|
8
Sonos
SONO
$1.88B
| $2.8M | 0.61% |
171,172
-113,192
| -40% | -$2.01M |
|
|
ROIVW
9
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
| $2.73M | 0.6% |
1,100,662
+147,709
| +16% | +$291K |
|
|
OSG
10
Octave Specialty Group
OSG
$256M
| $2.67M | 0.58% |
187,568
| – | – |
|
|
11
Arcutis Biotherapeutics
ARQT
$3.39B
| $2.21M | 0.48% |
+232,201
| New | +$2.58M |
|
|
HTZWW
12
Hertz Global Holdings Warrants
HTZWW
$67.7M
| $1.25M | 0.27% |
123,494
| – | – |
|
|
MNK
13
DELISTED
Mallinckrodt plc
MNK
| $691K | 0.15% |
585,602
+568,346
| +3,294% | +$2.02M |
|
|
14
Burford Capital
BUR
$935M
| – | – |
-274,329
| Closed | -$3.03M |
|
Similar funds
UB
FPA
FPP
SC
CFG
DS
MNA
NAMA
Two Seas Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Two Seas Capital held 14 positions worth $457M, up 320% from $109M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Two Seas Capital deployed $320M of net new capital in Q2 2023, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Indivior Pharmaceuticals: 13,668,919 shares worth $325M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 74% a quarter earlier, followed by Communication Services and Materials.
On the sell side, the largest reduction was Hertz, an estimated $5.06M trimmed.
- Two Seas Capital's largest Q2 2023 buy was Indivior Pharmaceuticals: 13,668,919 shares worth $325M.
- Two Seas Capital added most to Meta Platforms (Facebook) in Q2 2023, an estimated $4.94M increase.
- Two Seas Capital's biggest Q2 2023 reduction was Hertz, cutting an estimated $5.06M.
- Two Seas Capital fully exited Burford Capital in Q2 2023, selling an estimated $3.03M.
- Two Seas Capital's ten largest holdings make up 99% of its $457M portfolio in Q2 2023.
- Two Seas Capital opened 3 new positions and closed 1 in Q2 2023.
- Two Seas Capital's portfolio value rose 320% quarter-over-quarter to $457M.
Based on Two Seas Capital's 13F filing for Q2 2023, filed 14 Aug 2023.